Catalog No.: PC-25505Not For Human Use, Lab Use Only.
KCC-07 is a potent, selective and BBB-penetrable inhibitor of MBD2 (methyl CpG binding domain protein 2), prevents binding of MBD2 to methylated DNA, reactivates ADGRB1 expression and prevents MDM2-mediated p53 polyubiquitination.
KCC-07 is a potent, selective and BBB-penetrable inhibitor of MBD2 (methyl CpG binding domain protein 2), prevents binding of MBD2 to methylated DNA, reactivates ADGRB1 expression and prevents MDM2-mediated p53 polyubiquitination. KCC-07 abrogated MBD2 binding to the ADGRB1 promoter and restored BAI1 mRNA and protein expression in BAI1-silent MB cells. KCC-07 inhibited MB cell growth in vitro, with induction of anti-proliferative BAI1/p53/p21 signaling. KCC-07 (100 mg/kg i.p.; 5 days/week) inhibited MB growth in vivo by reactivating the BAI1-p53 tumor suppressor axis.
Physicochemical Properties
M.Wt
269.32
Formula
C14H11N3OS
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
3-((4-(Pyridin-2-yl)thiazol-2-yl)amino)phenol
References
1. Lee D, et al. Exp Neurobiol. 2025 Aug 31;34(4):138-146.
2. Peng B, et al. Ann Med. 2025 Dec;57(1):2458207.
3. Dan Zhu, et al. Cancer Cell. 2018 Jun 11;33(6):1004-1016.e5.
